PLX R&D Expense Growth
Protalix Biotherapeutics Inc · R&D Expense Growth
PLX R&D Expense Growth
Latest reported46.91%period ending
PLX FY R&D Growth (YoY) (0.00% → 46.91%)
Latest values, visible window
High-resolution chart · PNG
PLX r&d expense growth history
Annual fiscal periods. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D Expense Growth |
|---|---|
| 46.9082% | |
| -24.121% | |
| -41.7595% | |
| -1.2948% | |
| -22.095% | |
| -14.4545% | |
| 33.8614% | |
| 15.5927% | |
| -5.1887% | |
| 51.8702% | |
| -26.7878% | |
| -6.4089% | |
| 1.8683% | |
| -7.583% | |
| 3.646% | |
| 38.4185% | |
| 24.3492% | |
| 35.3005% | |
| 145.1582% | |
| 48.8649% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% |